Cancer Research Institute Executive Director, Dr. Jill O’Donnell-Tormey, to Present Keynote at Cancer Immunotherapy Confer

MD Becker Partners and BioBusiness.TV to Host Exclusive Conference Event & Televised Series “Cancer Immunotherapy: A Long Awaited Reality” on October 21, 2010 in New York City

NEW YORK--(BUSINESS WIRE)-- MD Becker Partners and BioBusiness.TV today announced that Jill O’Donnell-Tormey, Ph.D., executive director of the Cancer Research Institute (CRI), is scheduled to present a keynote address titled “The Future of Cancer Vaccine Development” at the Cancer Immunotherapy: A Long Awaited Reality conference taking place October 21, 2010, at the New York Academy of Medicine in New York.

“As an organization that for nearly 60 years has focused on transforming patient care by advancing new immune system-based cancer therapies, we believe that we are entering a new and exciting era in harnessing the immune system to treat, control, and prevent cancer,” said Dr. O’Donnell-Tormey.

Dr. O’Donnell-Tormey’s presentation, scheduled for 8:00 a.m. Eastern Time, October 21, will include a review of recent progress in cancer immunotherapy, CRI’s vision for the future of the field, and highlights from CRI’s 18th Annual International Cancer Immunotherapy Symposium to be held October 6-8, 2010, at the Millennium Conference Center in New York City.

Throughout the October 21 conference, event hosts will also be conducting on-camera interviews to be incorporated into an original televised series expected to consist of ten episodes, structured and narrated to review the major breakthroughs and issues in cancer immunotherapy today, and featuring renowned experts in the field. The series will be broadcast online and accessible free of charge to visitors.

Highlights of the conference will include:

  • Presentations by leading companies and institutions with active immunotherapies in development, including Bavarian Nordic A/S and the National Cancer Institute, BioSante Pharmaceuticals, Biovest International, Celldex Therapeutics, Dendreon Corporation, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, Northwest Biotherapeutics, Prima BioMed Ltd, Provectus Pharmaceuticals, Quantum Immunologics, and others
  • Overview of appropriate choices of clinically relevant endpoints for U.S. licensing approval
  • Discussion from leading researchers on the clinical application of cancer vaccines and issues related to the development of surrogate markers that can reduce the time and expense associated with clinical trials
  • Presentations on manufacturing issues associated with the production of autologous vaccines
  • Wall Street and investor perspectives on the cancer immunotherapy landscape

“Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy,” said Michael Becker of MD Becker Partners, a co-host of the program. “In view of recent progress, that hope is now becoming reality.”

“With approval of the first active cancer immunotherapy product in the U.S. and nearly a dozen programs in pivotal Phase 3 development, it is an appropriate time to bring together the founding visionary scientists, clinicians, entrepreneurs, key investors, and other stakeholders to exchange information and highlight opportunities in the expanding cancer immunotherapy universe,” said Jean-Loup Romet-Lemonne of BioBusiness.TV, which is co-hosting the program.

The agenda for the Cancer Immunotherapy: A Long Awaited Reality conference includes keynotes and plenary discussions, roundtable lunch conversations with experts, a focused science and industry track, as well as intimate networking opportunities to meet the needs of all attendees. Pre-registration is required and attendance is limited to 150 individuals on a first-come basis. To register, or to obtain more information, including a comprehensive and up-to-date list of presenting companies, please visit the News & Events section at http://www.mdbpartners.com or contact MD Becker Partners directly at [email protected].

About the Cancer Research Institute

The Cancer Research Institute (CRI), established in 1953, is the world’s only non-profit organization that is dedicated exclusively to transforming cancer patient care by advancing scientific efforts that are leading to new and effective immune system-based strategies to treat, control, and prevent cancer. Guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and twenty-nine members of the National Academy of Sciences, CRI has invested nearly $200 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities, and has contributed to many of the key scientific advances that have led to the recent explosion of interest in the potential for immunotherapy to change the face of cancer treatment. To accelerate the pace of progress in the field, CRI convenes and coordinates global collaborations among academics, industry scientists and decision makers, regulatory representatives, and health research associations focused on discovery, development, and refinement of new cancer immunotherapies. A founding visionary and scientific leader in tumor immunology, CRI is helping to shape the emerging field of immuno-oncology, and is ushering in a new era of medical progress to bring more treatment options to cancer patients sooner. For more information, visit http://www.cancerresearch.org.

About MD Becker Partners

MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. We also work with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic advisor and partner, we provide a full range of services to help our clients increase visibility, unlock stakeholder value, and access resources to grow their business. To accomplish this, we integrate relations, strategy, and operational capabilities and apply them to carefully conceived and expertly enacted tactics.

In early April 2010, MD Becker Partners published a 150-page industry report titled “Cancer Vaccine Therapies: Failures and Future Opportunities,” which included an overview of the cancer immunotherapy market, interviews with several key opinion leaders, profiles of nearly 40 companies, and a discussion of the scientific, clinical, and commercial considerations for major industry participants. For more information visit http://www.mdbpartners.com.

About BioBusiness.TV

BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. We create video-based industry focused business news and analysis programs. We produce and syndicate videos ranging from news and stock picks, to equity analyst insights, as well as C-level executive interviews on strategy, management, policy, marketing, science, and more.

BioBusiness.TV’s latest Original Series, “The Stem Cell Review,” is a 10-part TV program on the science, medical applications, and business of stem cells, which provides a clear and concise understanding of the state of stem cells today, with the additional depth and expertise you would come to expect from the most renowned authorities in the field. For more information, visit http://www.biobusiness.tv.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6441589&lang=en



CONTACT:

Cancer Research Institute
Brian M. Brewer, +1-212-688-7515, ext. 242
[email protected]
or
MD Becker Partners LLC
Michael Becker, +1-267-756-7094
[email protected]
or
BioBusiness.TV
Jean-Loup Romet-Lemonne, +1-917-915-2073
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Entertainment  TV and Radio  Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Consulting

MEDIA:

Logo
 Logo
Photo
 Photo
Photograph of Michael D. Becker, founder and senior partner, MD Becker Partners LLC (Photo: Business Wire)

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.